Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)’s stock price was down 17.7% on Wednesday . The company traded as low as $6.71 and last traded at $7.31, approximately 2,114,280 shares traded hands during trading. An increase of 216% from the average daily volume of 670,113 shares. The stock had previously closed at $8.88.
A number of equities analysts recently weighed in on BCLI shares. ValuEngine lowered shares of Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 13th. Maxim Group restated a “buy” rating and set a $9.00 target price on shares of Brainstorm Cell Therapeutics in a research report on Friday, November 15th.
The stock’s 50-day moving average is $4.76 and its two-hundred day moving average is $4.09. The stock has a market cap of $200.40 million, a P/E ratio of -6.90 and a beta of 1.34.
In related news, CFO Preetam Shah bought 11,600 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was purchased at an average price of $4.12 per share, for a total transaction of $47,792.00. 21.20% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in Brainstorm Cell Therapeutics by 9.5% during the fourth quarter. Bank of America Corp DE now owns 22,991 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,991 shares during the last quarter. Sunbelt Securities Inc. bought a new position in Brainstorm Cell Therapeutics during the fourth quarter valued at $5,350,000. Tower Research Capital LLC TRC lifted its position in Brainstorm Cell Therapeutics by 1,640.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,155 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 10,514 shares during the last quarter. CFO4Life Group LLC bought a new position in Brainstorm Cell Therapeutics during the fourth quarter valued at $51,000. Finally, Virtu Financial LLC bought a new position in Brainstorm Cell Therapeutics during the third quarter valued at $51,000. Institutional investors and hedge funds own 9.17% of the company’s stock.
About Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
See Also: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.